Xlife Sciences AG's revenue for the
six
months ended in Dec. 2025 was CHF-0.08 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was CHF0.28 Mil.
Xlife Sciences AG's Revenue per Share for the
six
months ended in Dec. 2025 was CHF-0.01.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was CHF0.04.
Warning Sign:
Xlife Sciences AG revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Xlife Sciences AG was -67.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -36.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -9.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 8 years, Xlife Sciences AG's highest 3-Year average Revenue per Share Growth Rate was 26.60% per year. The lowest was -36.10% per year. And the median was -1.90% per year.
Xlife Sciences AG (XSWX:XLS) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Xlife Sciences AG Revenue Related Terms
Xlife Sciences AG Revenue Historical Data
* Premium members only.
The historical data trend for Xlife Sciences AG's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Xlife Sciences AG's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xlife Sciences AG Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's Revenue distribution charts can be found below:
* The bar in red indicates where Xlife Sciences AG's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF0.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xlife Sciences AG (XSWX:XLS) has a Revenue of CHF0.28 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Xlife Sciences AG and its competitors.
Is Xlife Sciences AG's Revenue too high?
Xlife Sciences AG's current Revenue is CHF0.28 Mil. Overall, Xlife Sciences AG has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Revenue compare to VRTX and REGN?
Xlife Sciences AG's Revenue of CHF0.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Xlife Sciences AG and its competitors. Xlife Sciences AG's current Revenue is CHF0.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.29, compared to a current price of CHF20.20 — trading 177.1% above its estimated fair value. The current Revenue is CHF0.28 Mil. Xlife Sciences AG's overall GF Score™ is 53/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current Revenue is CHF0.28 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of CHF20.20 is trading 177.1% above its estimated GF Value™ of CHF7.29.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for XSWX:XLS:
Revenue: CHF0.28 Mil
GF Value™: CHF7.29 vs. price of CHF20.20 (177.1% above fair value)
No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
53GF Score
Get the complete analysis for XSWX:XLS
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:XLS has been successfully added to your 
